by Madaline Spencer | Aug 8, 2025
The U.S. Food and Drug Administration (FDA) has approved Alhemo (concizumab) injection as a once-daily prophylaxis treatment to prevent or reduce frequency of bleeding episodes in patients ages 12 years and older with hemophilia A or B without inhibitors. This is an...
by James Radke, PhD | May 27, 2025
Sanjay Ahuja, MD, Pediatric Hematologist, Chief Medical and Informatics Officer at Innovative Hematology and the Indiana Hemophilia and Thrombosis Center (IHTC), discusses the U.S. Food and Drug Administration (FDA) approval of Qfitlia (fitusiran) for patients with...
by Madaline Spencer | Apr 1, 2025
The U.S. Food and Drug Administration (FDA) has approved Qfitlia (fitusiran) for the treatment of hemophilia A and B with or without inhibitors. Hemophilia is an inherited bleeding disorder in which the blood does not clot normally. People with the condition will...
by Madaline Spencer | Mar 19, 2025
Steven Pipe, MD, Professor of Pediatrics and Pathology at the University of Michigan, discusses positive follow-up results in patients with hemophilia B treated with Hemgenix (etranacogene dezaparvovec-drlb). Hemophilia B is a rare bleeding disorder that...
by Madaline Spencer | Apr 12, 2024
Brahm Goldstein, MD, Vice President, Research and Development, Hematology at CSL Behring, discusses HEMGENIX, a pivotal gene therapy for hemophilia B. Hemophilia B is a bleeding disorder that slows the blood clotting process, caused by genetic changes in...